Shots:

• The P-III PANORAMA trial involves assessing of Eylea (q8w- q16w) vs PBO (sham injection) in 402 patients with moderately-severe and severe NPDR for 52 weeks
• P-III PANORAMA trial results: Development of VTCs (3%- 4% vs 20%); CI-DME occurrence (8%- 7% vs 26%); Collective occurrence of VTC & CI-DME (11%- 10% vs 41%). The avg. no.of IV @8wks  &16 wks. are (8.9 & 5.5) respectively
• Eylea IV a prefilled syringe is a VEGF inhibitor formulated for eye. Regeneron has submitted its sBLA in diabetic retinopathy based on 24 wks. results under the US FDA with PDUFA date 13 May- 2019

/ article | Ref: Regeneron | Image: Eylea